Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Simvastatin Myopathy Rate Spells Trouble For High Doses In “A to Z” Trial

This article was originally published in The Tan Sheet

Executive Summary

An increased rate of myopathy in study participants taking an 80 mg dose of Merck's Zocor (simvastatin) suggests that high doses of the drug "should be used with caution," according to an editorial slated for publication in the Sept. 15 Journal of the American Medical Association

You may also be interested in...

J&J/Merck Developing Mevacor 20 Mg As OTC For Moderate Risk Group

J&J/Merck's second try at an Rx-to-OTC switch for Mevacor (lovastatin) involves a 20 mg dose targeted at a moderate to intermediate risk group, according to VP-Regulatory & Scientific Affairs Edwin Hemwall, PhD

Lipitor v. Pravachol Studies Raise Questions On Utility Of OTC-Dose Statins

Two recently published clinical trials involving statins that report a clear and substantial benefit from intensive LDL-cholesterol lowering versus moderate reduction may dampen prospects for switching the drugs OTC in the U.S

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts